SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.36 (-2.65%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.36 (-2.65%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.36 (-2.65%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.36 (-2.65%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
NYSE:LCI

Lannett - LCI Stock Forecast, Price & News

$0.49
+0.01 (+2.26%)
(As of 10/7/2022 10:27 AM ET)
Add
Compare
Today's Range
$0.49
$0.49
50-Day Range
$0.45
$0.63
52-Week Range
$0.43
$2.78
Volume
314 shs
Average Volume
176,423 shs
Market Capitalization
$21.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Lannett MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
11.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Lannett in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$15,268 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.68) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.08 out of 5 stars

Medical Sector

1059th out of 1,075 stocks

Pharmaceutical Preparations Industry

530th out of 537 stocks

LCI stock logo

About Lannett (NYSE:LCI) Stock

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Receive LCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lannett and its competitors with MarketBeat's FREE daily newsletter.

LCI Stock News Headlines

Lannett Company, Inc. (LCI)
Lannett (NYSE:LCI) Now Covered by StockNews.com
Earnings Preview: Lannett - Benzinga
See More Headlines
Receive LCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lannett and its competitors with MarketBeat's FREE daily newsletter.

LCI Company Calendar

Last Earnings
8/24/2022
Today
10/07/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
51601210
Employees
810
Year Founded
N/A

Profitability

Net Income
$-231,620,000.00
Pretax Margin
-68.68%

Debt

Sales & Book Value

Annual Sales
$340.58 million
Book Value
($5.83) per share

Miscellaneous

Free Float
36,658,000
Market Cap
$21.18 million
Optionable
Optionable
Beta
0.97

Key Executives

  • Mr. Timothy C. CrewMr. Timothy C. Crew (Age 61)
    CEO & Director
    Comp: $999.47k
  • Mr. John KozlowskiMr. John Kozlowski (Age 50)
    VP of Fin., CFO & Principal Accounting Officer
    Comp: $537.48k
  • Mr. John M. Abt (Age 57)
    VP and Chief Quality, Information Technology & Operations Officer
    Comp: $491.53k
  • Mr. Samuel H. Israel (Age 60)
    Gen. Counsel & Chief Legal Officer
    Comp: $526.15k
  • Ms. Maureen M. Cavanaugh (Age 62)
    Sr. VP & Chief Commercial Operations Officer
    Comp: $551.27k
  • Ms. Kristie Stephens
    Chief Compliance Officer & VP of Regulatory Affairs
  • Mr. Grant Brock
    VP of Operations













LCI Stock - Frequently Asked Questions

How have LCI shares performed in 2022?

Lannett's stock was trading at $1.62 at the beginning of the year. Since then, LCI stock has decreased by 70.2% and is now trading at $0.4821.
View the best growth stocks for 2022 here
.

Are investors shorting Lannett?

Lannett saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 3,890,000 shares, a decline of 7.6% from the August 15th total of 4,210,000 shares. Based on an average trading volume of 223,900 shares, the short-interest ratio is currently 17.4 days. Currently, 11.9% of the shares of the stock are short sold.
View Lannett's Short Interest
.

When is Lannett's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our LCI earnings forecast
.

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) announced its quarterly earnings results on Wednesday, August, 24th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.02. The business had revenue of $74.19 million for the quarter, compared to analysts' expectations of $74.65 million. During the same quarter last year, the company posted ($0.19) EPS.

What guidance has Lannett issued on next quarter's earnings?

Lannett issued an update on its FY 2023 earnings guidance on Tuesday, September, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $275.00 million-$300.00 million, compared to the consensus revenue estimate of $332.05 million.

What is Timothy Crew's approval rating as Lannett's CEO?

9 employees have rated Lannett Chief Executive Officer Timothy Crew on Glassdoor.com. Timothy Crew has an approval rating of 28% among the company's employees. This puts Timothy Crew in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lannett own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lannett investors own include Akorn (AKRX), Skechers U.S.A. (SKX), Integrated Device Technology (IDTI), Bank of America (BAC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Rite Aid (RAD) and NVIDIA (NVDA).

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How do I buy shares of Lannett?

Shares of LCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $0.48.

How much money does Lannett make?

Lannett (NYSE:LCI) has a market capitalization of $20.71 million and generates $340.58 million in revenue each year. The company earns $-231,620,000.00 in net income (profit) each year or ($5.73) on an earnings per share basis.

How many employees does Lannett have?

The company employs 810 workers across the globe.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The official website for the company is www.lannett.com. The company can be reached via phone at (215) 333-9000 or via fax at 215-333-9004.

This page (NYSE:LCI) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.